Navigation Links
UAB joins elite brain cancer research group
Date:7/9/2008

BIRMINGHAM, Ala. Brain cancer experts at the University of Alabama at Birmingham (UAB) have been selected for membership in the Ivy Genomics-Based Medicine Project. The project is a national consortium of cutting-edge hospitals and academic centers working to improve treatment and survival for patients with a kind of malignant brain tumor called a glioma.

As part of the nine-member consortium, UAB will serve as the only research site in the Southeast. UAB is one of four consortium members working in conjunction with its own National Cancer Institute-designated comprehensive cancer center and with a Specialized Program of Research Excellence (SPORE) in brain cancer.

"Being named to this project is a huge honor for us, and it shows we've kept pace and excelled in collaborative and translational research objectives," said G. Yancey Gillespie, Ph.D., UAB professor of neurosurgery and principal investigator for the Ivy Genomics-Based Medicine Project.

Gliomas are tumors that arise by transformation of the body's glial cells, which make up 90 percent of the brain and spinal cord and normally work in concert with neurons. The consortium members strive to unravel how genetic differences between gliomas can lead to more effective and even personalized treatments for patients.

The project will categorize tumors using sophisticated molecular profiling and, for the first time, test each brain tumor against a wide spectrum of treatments to match DNA markers with differences in cancer-fighting response.

"Currently, all patients get basically the same treatment without taking into account the genetic profile of their tumor," said Catherine Ivy, founder of the Ivy Foundation and the driving force behind the genomic project.

"The end goal of this research initiative is to identify how tumors with different genetic features respond to a set of treatment regimens and ultimately, it is hoped, provide physicians with the tools they need to offer brain tumor patients the most effective treatment options," Ivy said.

UAB's membership in the Ivy Genomics-Based Medicine Project is focused on the group's first stage, which has an intensive 18-month research timeline. The nine academic laboratories will use that period to screen dozens of anti-cancer drugs in animal models that help predict tumor-fighting response.

Information from those screenings and other genetic profiling will be linked and analyzed through a secure, real-time computer network. The project's second phase will likely involve human testing of anti-cancer drugs.

Gillespie said the genomic approach has the potential to generate several "firsts" in brain cancer research. "We already are working across disciplines: neuro-oncology, neurosurgery, neuroradiology, neuropathology, pharmacology and biomedical engineering," he said. "This research promises to have a significant impact on the way we treat this disease in the future."


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Global Health Progress Joins WHO and DNDi to Call For Increased Commitments to Fighting Neglected Tropical Diseases
2. Dr. Kenneth L. Byrd Joins SteriFx Inc.
3. Leading Vaccine Expert Joins IAVI
4. Marshall Norris Joins NavigatorMD as Director of Business Development and Sales
5. Dr. Howard Epstein Joins Blue Cross as Medical Director for Commercial Operations and Clinical Design
6. Uroplasty Joins the Russell Microcap Index
7. Marc Andreessen Joins Facebook Board of Directors
8. Jerry Steffl Joins Prime Therapeutics as Vice President, Government Affairs
9. Former Assistant US Surgeon General Woodie Kessel, MD, MPH, Joins Academic Network LLC as Senior Scientific Advisor
10. Karen Haney Joins The Turning Point Group as Partner and Vice President of Client Services - Healthcare
11. Bruce Palsulich Joins Relsys International as Chief Innovation & Strategy Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology: